# Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke

Study · id `cardio:ct-nct07040085` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07040085](<https://clinicaltrials.gov/study/NCT07040085>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07040085

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 892 participants.

## Technical summary

Registry record NCT07040085. Randomized; double masking; primary purpose treatment. Start 2025-08-05 (anticipated); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 892 participants (planned count; ClinicalTrials.gov record NCT07040085, source copy `cardio:ctgov-nct07040085-2025-06-26`, retrieved 2026-10-26)
- Planned start: 2025-08-05 (anticipated) (ClinicalTrials.gov record NCT07040085, source copy `cardio:ctgov-nct07040085-2025-06-26`, retrieved 2026-10-26)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07040085, source copy `cardio:ctgov-nct07040085-2025-06-26`, retrieved 2026-10-26)
- Completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07040085, source copy `cardio:ctgov-nct07040085-2025-06-26`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07040085-2025-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke
- Condition: Stroke
- Intervention (Drug): Y-6
- Intervention (Drug): Y-6 placebo
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: Neurodawn Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)
- Registry lists this organization as a collaborator: Neurodawn Pharmaceutical Co., Ltd. (`cardio:org-neurodawn-pharmaceutical-co-ltd`)

## Provenance

Content hash: b40810a1121f2cd7603e66a323e639398bcbc1d9d108f88a00f6764ebc0a739e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
